The root causes of atherosclerosis lie in cellular events that precede the clinical presentation of the disease by many years. The initiating events centre around the response of endothelial cells to chronic injury, such as that sustained in hypercholesterolemia. These responses involve the activation, attachment and migration of leucocytes and platelets.
DaviesPFReidyMAGoodeTBBowyerDE: Scanning electron microscopy in the evaluation of endothelial injury of the fatty lesion in atherosclerosisAtherosclerosis1976, 25:125–130.
2.
MinickCRStemermanMGInsullW: Effect of regenerating endothelium on lipid accumulation in the arterial wallProc Natl Acad Sci USA1977, 74:1724–1728.
3.
MartinJFBoothRFGMoncadaS: Arterial wall hypoxia following thrombosis of the vasa vasorum is an initial lesion in atherosclerosisEur J Clin Invest1991, 21:355–359. The authors present evidence that external compression of an artery produces atherosclerosis and propose that hypoxia of the arterial media secondary to occlusion of the vasa vasorum is important in atherogenesis.
4.
LefroyDCCrakeTUrenNGDaviesGJMaseriA: Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humansCirculation1993, 88:43–54. In-vivo human evidence that nitric oxide mediates coronary artery endothelium-dependent vasodilatation.
5.
LudmerPLSelwynAPShookTLWayneRRMudgeGHAlexanderRW: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteriesN Engl J Med1986, 315:1046–1051. A description of the abnormal endothelium-dependent responses of atherosclerotic human arteries in vivo.
6.
VitaJATreasureCBNabelEGMcLenachanJMFishRDYeungAC: The coronary vasomotor response to acetylcholine relates to risk factors for coronary artery diseaseCirculation1990, 81:491–497. The abnormal endothelial response to acetylcholine is not confined to overtly diseased arteries but also occurs in patients with risk factors for coronary artery disease.
7.
DrexlerHZeiherAMMeinzerKJustH: Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginineLancet1991, 338:1546–1550.
8.
DaviesPFRobotewskyjAGriemMLDullROPolacekDC: Haemodynamic forces and vascular cell communication in arteriesArch Pathol Lab Med1992, 116:1301–1306. A useful review of the mechanisms involved in the endothelial response to shear stress.
9.
RossR: The pathogenesis of atherosclerosis – an updateN Engl J Med1986, 314:488–500. A key review of atherogenesis.
10.
OlesenSPClaphamDEDaviesPF: Haemodynamic shear stress activates a K+ current in vascular endothelial cellsNature1988, 331:168–170. Stimulus-response coupling of haemodynamic forces to endothelial cells was shown by this study to be, at least in part, regulated by a potassium-selective shear stress-activated ionic current.
11.
GerritsenMEBloorCM: Endothelial cell gene expression in response to injuryFASEB J1993, 7:523–532. The endothelial cell perception of, and reaction to, injury via regulation of gene expression is reviewed.
12.
ResnickNCollinsTAtkinsonWBonthronDTDeweyCFGimborneMA: Platelet-derived growth factor-β chain promoter contains a cis-acting fluid shear stress-responsive elementProc Natl Acad Sci USA1993, 90:4591–4595. An important observation linking PDGF production with shear stress at a molecular level.
13.
LangilleBLO'DonnellF: Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependentScience1986, 231:405–407.
14.
RossR: The pathogenesis of atherosclerosis: A perspective for the 1990sNature1993, 362:801–809. The pre-eminent recent review of the mechanisms of atherogenesis.
15.
Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin StudyLancet1994, 344:1383–1389. A large randomized trial of the effect of cholesterol-lowering with simvastatin in patients with coronary artery disease. The treatment produced impressive reductions in mortality and morbidity. The relative risk of death in the treatment group was 0.70.
16.
GoldsteinJLBrownMS: The low-density lipoprotein pathway and its relations to atherosclerosisAnnu Rev Biochem1977, 46:897–930.
17.
GerrityRGNaitoHKRichardsonMSchwartzCJ: Dietary induced atherogenesis in swineAm J Pathol1979, 95:775–792.
18.
BrownMSGoldsteinJL: Receptor-mediated control of cholesterol metabolismScience1976, 191:150–154. This report describes how the LDL receptor functions in the cellular uptake of cholesterol. This work led to the development of the HMG-CoA reductase inhibitors.
SteinbergDParthasarathySCarewTEKhooJCWitztumJL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicityN Engl J Med1989, 320:915–924. An important review of the mechanisms and effects of the oxidation of LDL.
QuinnMTParthasarathySFongLGSteinbergD: Oxidatively modified low-density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesisProc Natl Acad Sci USA1987, 84:2995–2998.
23.
MorelDWDiCorlettoPEChisolmGM: Endothelial and smooth muscle cells alter low-density lipoprotein in vitro by free-radical oxidationArteriosclerosis1984, 4:357–364.
24.
CushingSDBerlinerJAValenteAJNavabMParhamiFGerrityR: Minimally modified low-density lipoprotein induces monocyte chemotactic protein-1 in human endothelial cells and smooth muscle cellsProc Natl Acad Sci USA1990, 87:5134–5138.
25.
ParumsDVBrownDLMitchinsonMJ: Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitisArch Pathol Lab Med1990, 114:383–387.
26.
VlaicuRNiculescoFRusHGCristeaA: Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaquesAtherosclerosis1985, 57:163–177.
27.
AviramM: Modified forms of low-density lipoprotein affect platelet aggregation in vitroThromb Res1989, 53:561–567.
28.
GoldsteinJLBrownMS: Familial hypercholesterolaemia In The Metabolic Basis of Inherited Disease. Edited by StanburyJB, New York: McGraw-Hill; 1972:672–712.
29.
LyonRTRunyon-HassADavisHRGlagovSZarinsCK: Protection from atherosclerotic lesion formation by reduction of artery wall motionJ Vase Surg1987, 74:1724–1728.
30.
RajmanIKendallMCrambR: The oxidation hypothesis of atherosclerosis [letter]Lancet1994, 344:1363–1364.
31.
MaPTSYamamotoTGoldsteinJLBrownMS: Increased mRNA for low-density lipoprotein receptor in livers of rabbits treated with I7α-ethinyl estradiolProc Natl Acad Sci USA1986, 83:792–796.
32.
HuberLASchefflerEPollTZieglerRDreselHA: 17 Betaestradiol inhibits LDL oxidation and cholesteryl ester formation in cultured macrophagesFree Radic Res Commun1990, 8:167–173.
33.
WeinerCPLizasoainIBaylisSAKnowlesRGCharlesIGMoncadaS: Induction of calcium-dependent nitric oxide synthases by sex hormonesProc Natl Acad Sci USA1994, 91:5212–5216. Treatment with estradiol but not progesterone increases calcium-dependent nitric oxide synthase activity in a variety of different tissues in the guinea-pig. This probably occurs via enzyme induction.
34.
ParasarathySBarnettJFongLG: High-density lipoprotein inhibits the oxidative modification of low-density lipoproteinBiochem Biophys Acta1990, 1044:275–283.
35.
MinickCRFabricantCGFabricantJLitrentaMM: Atheroarteriosclerosis induced by infection with a herpes virusAm J Pathol1979, 96:673–706.
36.
BendittEPBarrettTMcDougallJK: Viruses in the aetiology of atherosclerosisProc Natl Acad Sci USA1983, 80:6386–6389.
37.
VisserMRTracyPBVercellottiGMGoodmanJLWhiteJGJacobHS: Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endotheliumProc Natl Acad Sci USA1988, 85:8227–8230. HSV infection promotes the formation of a procoagulant surface in human endothelial cells in vitro.
38.
CybulskyMIGimbroneMA: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesisScience1992, 251:788–791.
39.
PostonRNHaskardDOCoucherJRGallNPJohnson-TideyRR: Expression of intercellular adhesion molecule-1 in atherosclerotic plaquesAm J Pathol1992, 140:665–673.
40.
ClintonSKLibbyP: Cytokines and growth factors in atherogenesisArch Pathol Lab Med1992, 116:1292–1300.
41.
CollinsT: Endothelial nuclear factor-κB and the initiation of the atherosclerotic lesionLab Invest1993, 68:499–508. The author presents evidence linking the oxidation-reduction state of the endothelial cell to expression of monocyte adhesion molecules via expression of a transcription factor complex.
42.
CushingSDBerlinerJAValenteAJTerritoMCNavabMParhamiF: Minimally modified low-density lipoprotein induces monocyte chemotactic protein-1 in human endothelial cells and smooth muscle cellsProc Natl Acad Sci USA1990, 87:5134–5138.
43.
RollinsBJYoshimuraTLeonardEJPoberJS: Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JEAm J Pathol1990, 136:1229–1233.
44.
NelkenNACoughlinSRGordonDWilcoxJN: Monocyte chemoattractant protein-1 in human atheromatous plaquesJ Clin Invest1991, 88:1121–1127. MCP-1 was identified using in-situ hybridization in atherosclerotic regions of human arteries.
45.
AquelNMBallRYWaldmannHMitchinsonMJ: Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodiesJ Pathol1985, 146:197–204.
46.
ClintonSKUnderwoodRHayesLShermanMLKufeDWLibbyP: Macrophage-colony stimulating factor gene expression in vascular cells and in experimental and human atherosclerosisAm J Pathol1992, 140:301–316.
47.
RosenfeldMYla-HerttualaSLiptonBOrdVAWitztumJLSteinbergD: Macrophage colony stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humansAm J Pathol1992, 140:291–300.
48.
WhiteJG: Platelets and atherosclerosisEur J Clin Invest1994, 24 (suppl 1):25–29.
49.
MarcusAJSafierLBHajjarKAUllmanHLIslamNBroekmanMJ: Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase: Thromboregulation by endothelial cellsJ Clin Invest1991, 88:1690–1696.
50.
MarcusAJSafierLB: Thromboregulation: Multicellular modulation of platelet reactivity in hemostasis and thrombosisFASEB J1993, 7:516–522. A review of the normal mechanisms behind platelet plug formation and the failure of thromboregulation in atherosclerosis.
51.
FaggiottoARossR: Studies of hypercholesterolaemia in the non-human primate. II. Fatty streak conversion to fibrous plaqueArteriosclerosis1984, 4:341–356.
52.
FusterVBowieWJLewisJCFassDNOwenCABrownAL: Resistance to arteriosclerosis in pigs with von Willebrand disease: Spontaneous and high-cholesterol-diet induced atherosclerosisJ Clin Invest1978, 61:722–730.
53.
Chamley-CampbellJHCampbellGRRossR: The smooth muscle cell in culturePhysiol Rev1985, 59:139–145.
54.
WilcoxJNSmithKMWilliamsLTSchwartzSMGordonD: Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridizationJ Clin Invest1988, 82:1134–1143.
55.
SchwartzSM: Serum-derived growth factor is thrombin?J Clin Invest1993, 91:4.
56.
RimmEBStampferMJAscherioAGiovannucciEColditzGAWillettWC: Vitamin E consumption and the risk of coronary artery disease in menN Engl J Med1993, 328:1450–1456. This large-scale prospective trial of treatment with vitamin E supplements showed a significant reduction in the risk of coronary artery disease.
57.
NabelEGYangZLiptaySSanHGordonDHaudenschildCC: Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivoJ Clin Invest1993, 91:1822–1829.
58.
OhnoTGordonDSanHPompiliVImperialeMNabelGJ: Gene therapy for vascular smooth muscle cell proliferation after arterial injuryScience1994, 265:781–784. An important study in which sensitivity to ganciclovir was induced in smooth muscle cells by adenoviral vectors. Subsequent exposure to the drug inhibited injury-induced smooth muscle proliferation.
59.
TakeshitaSZhengLPAsaharaTReissenRBrogiEFerraraN: In-vivo evidence of enhanced angiogenesis following direct arterial gene transfer of the plasmid encoding vascular endothelial growth factor [abstract]Circulation1993, 88:1476.
60.
The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplastyN Engl J Med1994, 330:956–961. A double-blind randomized trial of a monoclonal antibody against the platelet GPIIb-IIIa receptor in 2099 patients undergoing high-risk coronary angioplasty. There was a 35% reduction in acute complications within 30 days of the procedure but an increase in bleeding complications.
